Krystal Biotech posts second-quarter results, outlines multiple late-2026 pipeline readouts

Krystal Biotech reported financial and operating results for the quarter ended June 30, 2026 on August 3, 2026. Global VYJUVEK net product revenue reached $119.2 million for the quarter, up 24% from the prior year period.¹ The company said it has now obtained more than 730 reimbursement approvals for VYJUVEK and grown its prescriber base to over 640 unique prescribers.¹

On international expansion, pricing talks with German authorities are expected to continue into the second half of 2026 and French talks into 2027, while Italy and Spain remain on track for launches before year end.¹ VYJUVEK was approved in the UK by the MHRA in May, received a Prix Galien UK award in June, and UK pricing discussions are now underway.¹ The company also plans to submit additional marketing applications in the second half of 2026, including in Switzerland and Australia.¹

In the pipeline, the IOLITE study of KB803 for corneal abrasions in DEB patients completed enrollment in April and remains on track for top-line data in the fourth quarter of 2026.¹ Enrollment of about 60 patients in the KB801 neurotrophic keratitis study, EMERALD-1, is expected to finish by year end.¹ For respiratory programs, the KB407 cystic fibrosis study is expected to complete enrollment of about five patients with interim results before year end,¹ and alignment with FDA on a registrational design is expected in the fourth quarter of 2026, with study initiation targeted for 2027.¹

In oncology, the KYANITE-1 dose expansion cohort combining inhaled KB707 with pembrolizumab showed a 31% objective response rate and 75% disease control rate in advanced NSCLC.¹ The company has enrolled three Gorlin syndrome patients in the OPAL-1 study and plans an interim update later this year.¹

Cash, cash equivalents and investments totaled $1.1 billion as of June 30, 2026.¹